Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Vascular Endothelial Growth Factor (VEGF) is crucial for tumor angiogenesis.
• Targeting VEGF pathways is a key strategy in cancer therapy.
• Dual targeting may overcome resistance and enhance efficacy.

Purpose of the Study:

• To evaluate the anti-tumour effects of combining bevacizumab (VEGF-depleting) with AZD2171 (VEGF receptor tyrosine kinase inhibitor).
• To assess the impact of this combination on tumor growth, vascular necrosis, and cell proliferation in a xenograft model.

Main Methods:

• Mice with human head and neck CAL33 xenografts were treated with vehicle, AZD2171, bevacizumab, or the combination.
• Tumor growth, vascular necrosis, cell proliferation, apoptosis markers (Bax/Bcl2 ratio), and HIF1-alpha expression were analyzed.

Main Results:

• The bevacizumab-AZD2171 combination demonstrated additive effects on tumor growth inhibition.
• Combination therapy significantly increased tumor vascular necrosis and decreased mature tumor cells.
• A substantial increase in the Bax/Bcl2 ratio and a decrease in HIF1-alpha expression were observed with the combination.

Conclusions:

• Dual VEGF pathway targeting with bevacizumab and AZD2171 shows synergistic anti-tumour activity.
• The combination therapy effectively targets tumor angiogenesis and promotes apoptosis.
• These findings provide a strong rationale for clinical trials of this dual-targeting strategy.